CROI 2024 Abstract eBook

Abstract eBook

Poster Abstracts

1078 National HIV Testing Trends and Sociodemographic Correlates in Black Cisgender or Transgender Women Xinyi Li 1 , Yijin Xiang 2 , Jincong Q. Freeman 3 , Yong G. Lee 4 1 George Washington University, Washington, DC, USA, 2 University of Southern California, Los Angeles, CA, USA, 3 University of Chicago, Chicago, IL, USA, 4 Rutgers University, Newark, NJ, USA Background: Black cisgender and transgender women are disproportionally impacted by HIV in the United States. Having high-risk behaviors related to HIV but not receiving HIV testing could lead to delayed diagnosis and treatment in this population. We investigated the trend of HIV testing and associated sociodemographic characteristics among Black cisgender and transgender women at risk for HIV. Methods: We analyzed data from the 2016-2020 Behavioral Risk Factor Surveillance System. Respondents who self-identified as Black, cisgender or transgender women, and reported high-risk behaviors were included. Variables examined in the analysis included ever been tested for HIV, age, education level, income, healthcare coverage, and geographic region. Unweighted counts and weighted percentages were used to describe study population's characteristics. Annual percent change (APC) and p-value were calculated to examine the trend of ever having been tested for HIV over 5 years, using the Joinpoint trend analysis software. The associations between sociodemographic characteristics and ever having HIV testing were assessed using multivariable logistic regression, controlling for explanatory variables with a p<0.05. Adjusted odds ratio (aOR) and 95% confidence intervals (95% CI) were reported. Results: Among 3,509 (weighted n= 4,129,231) Black cisgender and transgender women (35 were excluded due to missing HIV testing status), 2,837 (83.1%) had ever been tested for HIV, and 647 (16.9%) had not. We observed a slight decrease in the percentages of HIV testing over 5 years, from 83.8% in 2016 to 79.2% in 2020 (APC = -1.29, p=0.5420). Black cisgender and transgender women aged 18-34 years (aOR: 0.47, 95% CI: 0.33-0.65) or ≥55 years (aOR: 0.18, 95% CI: 0.11-0.31) were less likely than women aged 35-54 years to get tested for HIV. Additionally, Black cisgender and transgender women with less than high school (aOR: 0.61, 95% CI: 0.38-0.99) or some post-high school (aOR: 0.63, 95% CI: 0.46-0.86) education were less likely to get tested for HIV compared to those with at least a college degree. Conclusion: In this nationally representative sample of Black cisgender and transgender women, more than one in 6 with high-risk behaviors had not been tested for HIV, and this trend remained stable over the 5-year period. To address the missed opportunities in HIV testing, HIV prevention programs might consider targeting 18-34 years old and ≥55 years Black women and those with a lower level of education.

On May 10th 2023 the WHO declared that MPOX is no longer a public health emergency of international concern. It was also emphasized that all countries worldwide should integrate MPOX prevention and care into national health programs to avoid future spreads. The clinical presentation of MPOX can range from mild to severe and mortality rates can vary. The high incidence rate further suggests that individuals who are infected but clinically asymptomatic may play an important role in the transmission of the virus. More research is needed to ascertain whether HIV can directly influence the clinical presentation in individuals affected by MPOX, focusing on the possibility of an asymptomatic course in this group of individuals. We undertook this study to assess the seroprevalence of IgG anti-MPV in a cohort of PLWH with no reported symptoms consistent with a diagnosis of MPOX, to try to analyze the actual size of the phenomenon of asymptomatic infections in clinical practice. Methods: From October 2022 to February 2023, we serially collected serum samples from PLWH attending our outpatient clinic for their routine analysis. IgG against MPV have been assessed on stored cryopreserved serum samples with an ELISA. No significant cross-reactivity or interference between anti-MPV IgG and analogues was reported. For the purpose of this study, only people with no previous reported vaccine against smallpox or MPOX nor previous clinical manifestations consistent with an MPX diagnosis were included. Results: A total of 104 PLWH were tested. 19 participants reported a previous vaccination against smallpox, 1 participant reported a previously confirmed diagnosis of MPOX. All the other 84 participants denied previous vaccination, infection or clinical manifestations consistent with MPX infection. Our analysis revealed 6 patients who tested IgG positive for MPX. Seroprevalence was equal to 7.1%. Demographical and viro-immunological characteristics of the entire population and PLWH who tested IgG positive are shown in Table 1. Conclusion: Our findings from this setting showed a mildly high IgG MPX prevalence among PLWH with no previous clinical manifestations, suggesting the possibility of an asymptomatic course of the MPX infection. Early detection and appropriate management of MPOX infected people are of utmost importance for global public health and appropriate clinical management. 1080 Impact of COVID-19 Pandemic on HIV Testing Among MSM: An Interrupted Time Series Analysis Emily J Green 1 , Lamia Khan 1 , Jamieson T. Jann 1 , Marjan Javanbakht 2 , Risa Flynn 1 1 Los Angeles LGBT Center, Los Angeles, CA, USA, 2 University of California Los Angeles, Los Angeles, CA, USA Background: No studies have examined the effects of the COVID-19 pandemic on HIV testing across substantial observation time among a large sample of gay, bisexual and other men who have sex with men (GBMSM), a priority population disproportionately impacted by HIV. We describe the extent to which COVID-19 pandemic-related disruptions to health clinic services impacted the level of HIV testing among sexual minority men in Los Angeles. Methods: Data comes from the Los Angeles LGBT Center's health services program, one of the nation's largest Federally Qualified Health Centers providing health services to LGBTQ+ individuals. We include GBMSM who are 15 years or older. The primary outcome measure is the average number of HIV tests per week. Interrupted time series analyses were used to model and test changes in HIV testing across three phases of the pandemic: a pre-pandemic phase from March 1, 2018 to March 15, 2020, a pandemic phase from March 16, 2020 to February 28, 2022, and an endemic phase, from March 1, 2022 to August 31, 2023, which signifies the full return of Center services. Weekly HIV testing is estimated overall and by race/ethnicity. Results: The sample included 25,844 unique participants (n=95,328 visits); 8% were Black/African American, 34% Hispanic/Latinx, 39% white, 8% Asian/ Pacific Islander, and 11% some other race/ethnicity. Most participants were between 25-39 years old (48%). The average number of tests conducted weekly across the pre-pandemic, pandemic, and endemic phases are 321, 231, and 288, respectively. There was nearly a 50% reduction in the level of HIV testing conducted weekly after the transition from the pre-pandemic to pandemic phase (Incident Rate Ratio (IRR): 0.53, 95%CI: 0.47, 0.60). The number of HIV

Poster Abstracts

1079 Seroprevalence of Mpox IgG Antibodies in a Cohort of PLWH in Rome During the 2022 Outbreak Pierluigi Francesco Salvo 1 , Rebecca Jo Steiner 1 , Damiano Farinacci 2 , Valentina Iannone 1 , Francesco Lamanna 1 , Rosa Anna Passerotto 1 , Alberto Borghetti 2 , Simona Di Giambenedetto 1 , Francesca Lombardi 2 1 Catholic University of the Sacred Heart, Rome, Italy, 2 IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy Background: The 2022 outbreak of MPOX has unveiled atypical epidemiological and clinical features, setting it apart from previous outbreaks.

CROI 2024 349